Giuseppe Curigliano, MD PhD, is Full Professor of Medical Oncology at the University of Milano and Chief of the Clinical Division of Early Drug Development at European Institute of Oncology, Milano, Italy. Dr. Curigliano is an expert in the field of advanced drug development in solid tumors, with specific interest in breast cancer. He has contributed to the development of many anticancer treatments actually available as standard of care in the treatment of multiple solid tumors. Since 2001 he is tenure-track and full-time cancer specialist at the European Institute of Oncology – one of the world’s leading cancer-research institutes and the premier Cancer Center in Italy, third in Europe and 12^th globally. He serves as member of the Italian Higher Health Council.

Dr. Curigliano serves ESMO as Chair of the Clinical Practice Guidelines Committee. He was awarded with the first ESO Umberto Veronesi Award in Vienna in 2017 and with the Fellowship of the European Academy of Cancer Sciences in Paris in 2017. Dr Curigliano was identified in 2022 as Clarivate™ world’s most influential researchers. Dr. Curigliano has contributed to over 670 peer-reviewed publications.